Loading clinical trials...
Loading clinical trials...
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Conditions
Interventions
Palovarotene
Locations
2
United States
University of California San Francisco, Division of Endocrinology and Metabolism
San Francisco, California, United States
University of Pennsylvania, Center for Research in FOP & Related Disorders
Philadelphia, Pennsylvania, United States
Start Date
December 7, 2015
Primary Completion Date
August 4, 2016
Completion Date
August 4, 2016
Last Updated
October 19, 2020
NCT04307953
NCT05394116
NCT06508021
NCT05027802
NCT04818398
NCT04665323
Lead Sponsor
Clementia Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions